Skip to main content
. Author manuscript; available in PMC: 2015 May 26.
Published in final edited form as: Breast Cancer Res Treat. 2010 Dec 18;126(3):779–789. doi: 10.1007/s10549-010-1301-5

Fig. 4.

Fig. 4

TMS reduces ductal hyperplasia from 5-month-old aromatase-transgenic mice. a From left to tight the panels represent: 1 before treatment whole mount, 2 after treatment whole mount, 3 after treatment with H and E sections shown. From top to bottom, the panels represent intact control, TMS given as 60 mg silastic implants, or Letrozole (CGS20267) given at 20 μg/mouse. b From left to right includes: 1 intact control, 2 TMS treatment in intact mice <5 months of age, 3 ovariectomized mice <5 months of age. c Metamorph analysis of whole duct structures (primary and secondary ducts + TDSABs). d Analysis restricted to TDSABs (tertiary ductal structures and alveolar buds). The TDSABs were graphed as the mean ± SE for % change of TDS. One-way ANOVA test showed a statistically significant difference between the TMS and control groups (P = 0.016)